다한증 치료 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 치료법별, 지역별 및 부문별 예측(2026-2033년)

Hyperhidrosis Treatment Market Summary

The global hyperhidrosis treatment market size was valued at USD 1.7 billion in 2025 and is projected to grow from USD 1.8 billion in 2026 to USD 3.2 billion by 2033, at a CAGR of 8.4% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.3% in 2025. The industry is driven by the need to manage excessive sweating affecting areas such as the underarms, palms, feet, and face.

Hyperhidrosis can interfere with daily activities, personal interactions, work performance, and quality of life, creating a need for effective and convenient treatment options. The market includes prescription antiperspirants, topical anticholinergic products, iontophoresis, botulinum toxin injections, oral medications, energy-based treatments, and surgical procedures. Treatment selection varies based on the affected body area, symptom severity, treatment response, and patient preference. Topical therapies have gained attention as non-invasive options, particularly for axillary hyperhidrosis, while procedural treatments continue to be used for patients who require longer-lasting symptom control. The market is also supported by improving recognition of hyperhidrosis as a medical condition rather than only a cosmetic concern. However, delayed diagnosis and limited patient awareness remain barriers to access to treatment. Overall, the market continues to develop through broader treatment availability and growing clinical attention.

Global Hyperhidrosis Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hyperhidrosis treatment market report based on type, treatment, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Primary Hyperhidrosis
• Secondary Hyperhidrosis
• Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
• Prescription Antiperspirants
• Topical Medications
• Oral Medications
• Botulinum Toxin Injections
• Iontophoresis
• Energy-Based Therapies
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Treatment
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Hyperhidrosis Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Hyperhidrosis Treatment Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
• 4.4. Primary Hyperhidrosis
  • 4.4.1. Primary Hyperhidrosis Market, 2021 - 2033 (USD Billion)
• 4.5. Secondary Hyperhidrosis
  • 4.5.1. Secondary Hyperhidrosis Market, 2021 - 2033 (USD Billion)

Chapter 5. Hyperhidrosis Treatment Market: Treatment Business Analysis

• 5.1. Treatment Market Share, 2025 & 2033
• 5.2. Treatment Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Billion)
• 5.4. Prescription Antiperspirants
  • 5.4.1. Prescription Antiperspirants Market, 2021 - 2033 (USD Billion)
• 5.5. Topical Medications
  • 5.5.1. Topical Medications Market, 2021 - 2033 (USD Billion)
• 5.6. Oral Medications
  • 5.6.1. Oral Medications Market, 2021 - 2033 (USD Billion)
• 5.7. Botulinum Toxin Injections
  • 5.7.1. Botulinum Toxin Injections Market, 2021 - 2033 (USD Billion)
• 5.8. Iontophoresis
  • 5.8.1. Iontophoresis Market, 2021 - 2033 (USD Billion)
• 5.9. Energy-Based Therapies
  • 5.9.1. Energy-Based Therapies Market, 2021 - 2033 (USD Billion)
• 5.10. Others
  • 5.10.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Hyperhidrosis Treatment Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2025 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 6.4. North America
  • 6.4.1. North America Hyperhidrosis Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. Canada Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.5. Europe
  • 6.5.1. Europe Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. UK Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.7. Latin America
  • 6.7.1. Latin America Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Brazil Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. Argentina Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Hyperhidrosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. AbbVie Inc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Botanix Pharmaceuticals Ltd.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Journey Medical Corporation
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Kaken Pharmaceutical Co., Ltd.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Miramar Labs, Inc. (miraDry)
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Dermadry Laboratories Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Merz Pharma GmbH & Co. KGaA
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Medytox Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. August Wolff GmbH & Co. KG Arzneimittel
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Hidrex GmbH
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives